Yes, topiramate increases the risk of kidney stones, particularly calcium phosphate stones, by inhibiting carbonic anhydrase in the kidney
Side effects are usually gastrointestinal (nausea, diarrhea) but serious adverse events are relatively uncommon
Senescent cell turnover slows with age providing an explanation for the Gompertz law
While emerging preclinical research suggests potential anti-inflammatory properties, there is currently no FDA-approved indication for GLP-1 medications in treating Crohn's disease or any inflammatory bowel disease
During this time, researchers also found GLP-1 receptors in the brain and pancreas, particularly in areas controlling appetite and reward
High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist